Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial.

Committee for the REMAP-CAP Investigators, Writing; M Higgins, Alisa; R Berry, Lindsay; Lorenzi, Elizabeth; Murthy, Srinivas; McQuilten, Zoe; R Mouncey, Paul; Al-Beidh, Farah; Annane, Djillali; M Arabi, Yaseen; Beane, Abi; van Bentum-Puijk, Wilma; Bhimani, Zahra; J M Bonten, Marc; A Bradbury, Charlotte; M Brunkhorst, Frank; Burrell, Aidan; Buzgau, Adrian; Buxton, Meredith; N Charles, Walton; Cove, Matthew; A Detry, Michelle; J Estcourt, Lise; O Fagbodun, Elizabeth; Fitzgerald, Mark; D Girard, Timothy; C Goligher, Ewan; Goossens, Herman; Haniffa, Rashan; Hills, Thomas; M Horvat, Christopher; T Huang, David; Ichihara, Nao; Lamontagne, Francois; C Marshall, John; F McAuley, Daniel; McGlothlin, Anna; P McGuinness, Shay; J McVerry, Bryan; D Neal, Matthew; D Nichol, Alistair; L Parke, Rachael; C Parker, Jane; Parry-Billings, Karen; E C Peters, Sam; F Reyes, Luis; M Rowan, Kathryn; Saito, Hiroki; S Santos, Marlene; T Saunders, Christina

doi:10.1001/jama.2022.23257

Public

Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial.

Shared by NobleBlocks on Jan 3, 2023 • 12:00 AM UTC

Authors:

Writing Committee for the REMAP-CAP Investigators

Alisa M Higgins

Lindsay R Berry

Abstract

Importance: The longer-term effects of therapies for the treatment of critically ill patients with COVID-19 are unknown. Objective: To determine the effect of multiple interventions for critically ill adults with COVID-19 on longer-term outcomes. Design, Setting, and Participants: Prespecified secon...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!